Descriptive Analysis of Ebola virus Proteins: Towards Development of Effective Therapeutics and Vaccines

References (163)

1. 1 Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution [DOI]
2. 2 HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress [DOI]
3. 3 Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model [DOI]
4. 4 A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: Implications for filovirus budding [DOI]
5. 5 Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury [DOI]
6. 6 Structural basis of West Nile virus neutralization by a therapeutic antibody [DOI]
7. 7 The Ebola Virus VP35 Protein Is a Suppressor of RNA Silencing [DOI]
8. 8 Ebola Zaire Virus Blocks Type I Interferon Production by Exploiting the Host SUMO Modification Machinery [DOI]
9. 9 Direct Type I IFN but Not MDA5/TLR3 Activation of Dendritic Cells Is Required for Maturation and Metabolic Shift to Glycolysis after Poly IC Stimulation [DOI]
10. 10 Advanced antisense therapies for postexposure protection against lethal filovirus infections [DOI]
11. 11 Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses [DOI]
12. 12 Ebola Virus Antibodies in Fruit Bats, Ghana, West Africa [DOI]
13. 13 Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever [DOI]
14. 14 Ebola Virus VP35 Antagonizes PKR Activity through Its C-Terminal Interferon Inhibitory Domain [DOI]
15. 15 Ebola virus uses clathrin-mediated endocytosis as an entry pathway [DOI]
16. 16 Phosphorylation of VP30 Impairs Ebola Virus Transcription [DOI]
17. 17 Structural basis for Marburg virus VP35–mediated immune evasion mechanisms [DOI]
18. 18 Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus [DOI]
19. 19 Viral RNA silencing suppressors (RSS): Novel strategy of viruses to ablate the host RNA interference (RNAi) defense system [DOI]
20. 20 Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge [DOI]
21. 21 Membrane binding and bending in Ebola VP40 assembly and egress [DOI]
22. 22 Association of the Caveola Vesicular System with Cellular Entry by Filoviruses [DOI]
23. 23 A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus [DOI]
24. 24 Chimpanzee adenovirus vaccine protects against Zaire Ebola virus [DOI]
25. 25 The immune gene repertoire of an important viral reservoir, the Australian black flying fox [DOI]
26. 26 Endoproteolytic Processing of the Ebola Virus Envelope Glycoprotein: Cleavage Is Not Required for Function [DOI]
27. 27 Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein [DOI]
28. 28 Release of Viral Glycoproteins during Ebola Virus Infection [DOI]
29. 29 Ebola and Marburg virus-like particles activate human myeloid dendritic cells [DOI]
30. 30 Delta-Peptide Is the Carboxy-Terminal Cleavage Fragment of the Nonstructural Small Glycoprotein sGP of Ebola Virus [DOI]
31. 31 Phosphorylation of Ebola Virus VP30 Influences the Composition of the Viral Nucleocapsid Complex [DOI]
32. 32 Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies [DOI]
33. 33 Ebola Virus Matrix Protein VP40 Uses the COPII Transport System for Its Intracellular Transport [DOI]
34. 34 A Single Intranasal Inoculation with a Paramyxovirus-Vectored Vaccine Protects Guinea Pigs against a Lethal-Dose Ebola Virus Challenge [DOI]
35. 35 Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association [DOI]
36. 36 The Ebola Virus Matrix Protein Penetrates into the Plasma Membrane [DOI]
37. 37 Oligomerization of Ebola Virus VP30 Is Essential for Viral Transcription and Can Be Inhibited by a Synthetic Peptide [DOI]
38. 38 Structural and Functional Characterization of Reston Ebola Virus VP35 Interferon Inhibitory Domain [DOI]
39. 39 The Ebola Virus Matrix Protein Deeply Penetrates the Plasma Membrane: An Important Step in Viral Egress [DOI]
40. 40 Molecular characterisation of Toll-like receptors in the black flying fox Pteropus alecto [DOI]
41. 41 Proteolytic Processing of the Ebola Virus Glycoprotein Is Not Critical for Ebola Virus Replication in Nonhuman Primates [DOI]
42. 42 Ebolavirus VP35 Coats the Backbone of Double-Stranded RNA for Interferon Antagonism [DOI]
43. 43 Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein [DOI]
44. 44 Monoclonal Antibodies Combined with Adenovirus-Vectored Interferon Significantly Extend the Treatment Window in Ebola Virus-Infected Guinea Pigs [DOI]
45. 45 Cloning, expression and antiviral activity of IFNγ from the Australian fruit bat, Pteropus alecto [DOI]
46. 46 Classification, Structure, and Replication of Filoviruses [DOI]
47. 47 Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry [DOI]
48. 48 Evidence against Ebola Virus sGP Binding to Human Neutrophils by a Specific Receptor [DOI]
49. 49 The nucleoprotein gene of ebola virus: Cloning, sequencing, and in vitro expression [DOI]
50. 50 The OrderMononegavirales [DOI]
51. 51 Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp [DOI]
52. 52 Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection [DOI]
53. 53 Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses [DOI]
54. 54 Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection [DOI]
55. 55 Comparative Analysis of Bat Genomes Provides Insight into the Evolution of Flight and Immunity [DOI]
56. 56 Processing of the Ebola virus glycoprotein by the proprotein convertase furin [DOI]
57. 57 The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3 [DOI]
58. 58 Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations [DOI]
59. 59 Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates [DOI]
60. 60 Ebola Virus VP40-Induced Particle Formation and Association with the Lipid Bilayer [DOI]
61. 61 Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates [DOI]
62. 62 Distinct Cellular Interactions of Secreted and Transmembrane Ebola Virus Glycoproteins [DOI]
63. 63 Ebola Virus VP24 Proteins Inhibit the Interaction of NPI-1 Subfamily Karyopherin α Proteins with Activated STAT1 [DOI]
64. 64 The Assembly of Ebola Virus Nucleocapsid Requires Virion-Associated Proteins 35 and 24 and Posttranslational Modification of Nucleoprotein [DOI]
65. 65 Ebola Virus Protein VP35 Impairs the Function of Interferon Regulatory Factor-Activating Kinases IKKε and TBK-1 [DOI]
66. 66 Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model [DOI]
67. 67 Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35 [DOI]
68. 68 Ebola Virus Glycoproteins Induce Global Surface Protein Down-Modulation and Loss of Cell Adherence [DOI]
69. 69 Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates [DOI]
70. 70 Mutual Antagonism between the Ebola Virus VP35 Protein and the RIG-I Activator PACT Determines Infection Outcome [DOI]
71. 71 Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice [DOI]
72. 72 The VP35 Protein of Ebola Virus Inhibits the Antiviral Effect Mediated by Double-Stranded RNA-Dependent Protein Kinase PKR [DOI]
73. 73 Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection [DOI]
74. 74 The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold [DOI]
75. 75 Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses [DOI]
76. 76 Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies [DOI]
77. 77 Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae [DOI]
78. 78 Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb [DOI]
79. 79 Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection [DOI]
80. 80 Identification of an antioxidant small-molecule with broad-spectrum antiviral activity [DOI]
81. 81 Emerging Role of the Host Restriction Factor Tetherin in Viral Immune Sensing [DOI]
82. 82 Identification of Continuous Human B-Cell Epitopes in the VP35, VP40, Nucleoprotein and Glycoprotein of Ebola Virus [DOI]
83. 83 Reverse Genetics Demonstrates that Proteolytic Processing of the Ebola Virus Glycoprotein Is Not Essential for Replication in Cell Culture [DOI]
84. 84 Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-l-homocysteine hydrolase inhibitor [DOI]
85. 85 Structural characterization and membrane binding properties of the matrix protein VP40 of ebola virus [DOI]
86. 86 Pathogenesis of Experimental Ebola Zaire Virus Infection in BALB/c Mice [DOI]
87. 87 Biochemical and Functional Characterization of the Ebola Virus VP24 Protein: Implications for a Role in Virus Assembly and Budding [DOI]
88. 88 The Nonstructural Small Glycoprotein sGP of Ebola Virus Is Secreted as an Antiparallel-Orientated Homodimer [DOI]
89. 89 Interferon Production and Signaling Pathways Are Antagonized during Henipavirus Infection of Fruit Bat Cell Lines [DOI]
90. 90 Association of Ebola Virus Matrix Protein VP40 with Microtubules [DOI]
91. 91 Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes [DOI]
92. 92 A Single Sublingual Dose of an Adenovirus-Based Vaccine Protects against Lethal Ebola Challenge in Mice and Guinea Pigs [DOI]
93. 93 Single-Particle Tracking Demonstrates that Actin Coordinates the Movement of the Ebola Virus Matrix Protein [DOI]
94. 94 Bat Mx1 and Oas1, but not Pkr are highly induced by bat interferon and viral infection [DOI]
95. 95 A Loop Region in the N-Terminal Domain of Ebola Virus VP40 Is Important in Viral Assembly, Budding, and Egress [DOI]
96. 96 Analysis of Ebola virus and VLP release using an immunocapture assay [DOI]
97. 97 Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic [DOI]
98. 98 Full-length Ebola glycoprotein accumulates in the endoplasmic reticulum [DOI]
99. 99 Crystallization and preliminary X-ray analysis of the matrix protein from Ebola virus [DOI]
100. 100 GP mRNA of Ebola Virus Is Edited by the Ebola Virus Polymerase and by T7 and Vaccinia Virus Polymerases1 [DOI]
101. 101 Natural adjuvants: Endogenous activators of dendritic cells [DOI]
102. 102 Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor [DOI]
103. 103 Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques [DOI]
104. 104 Human Ebola Outbreak Resulting from Direct Exposure to Fruit Bats in Luebo, Democratic Republic of Congo, 2007 [DOI]
105. 105 Ebola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear Accumulation [DOI]
106. 106 Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study [DOI]
107. 107 Investigating the zoonotic origin of the West African Ebola epidemic [DOI]
108. 108 Role of Endosomal Cathepsins in Entry Mediated by the Ebola Virus Glycoprotein [DOI]
109. 109 Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys [DOI]
110. 110 Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques [DOI]
111. 111 Cutting Edge: Impairment of Dendritic Cells and Adaptive Immunity by Ebola and Lassa Viruses [DOI]
112. 112 Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP [DOI]
113. 113 Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies [DOI]
114. 114 Ebola virus-like particles protect from lethal Ebola virus infection [DOI]
115. 115 Structural Rearrangement of Ebola Virus VP40 Begets Multiple Functions in the Virus Life Cycle [DOI]
116. 116 Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail [DOI]
117. 117 Antibody-Dependent Enhancement of Ebola Virus Infection [DOI]
118. 118 Effects of Ebola Virus Glycoproteins on Endothelial Cell Activation and Barrier Function [DOI]
119. 119 Functional Mapping of the Nucleoprotein of Ebola Virus [DOI]
120. 120 Structure of the Ebola VP35 interferon inhibitory domain [DOI]
121. 121 Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates [DOI]
122. 122 Ebolavirus Proteins Suppress the Effects of Small Interfering RNA by Direct Interaction with the Mammalian RNA Interference Pathway [DOI]
123. 123 Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever [DOI]
124. 124 Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression [DOI]
125. 125 mAbs and Ad-Vectored IFN-α Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and Symptoms [DOI]
126. 126 Enhanced Protection against Ebola Virus Mediated by an Improved Adenovirus-Based Vaccine [DOI]
127. 127 Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names [DOI]
128. 128 Crystal structure of the matrix protein VP40 from Ebola virus [DOI]
129. 129 The Matrix Protein VP40 from Ebola Virus Octamerizes into Pore-like Structures with Specific RNA Binding Properties [DOI]
130. 130 Mutational Analysis of the Putative Fusion Domain of Ebola Virus Glycoprotein [DOI]
131. 131 Assessment of a Vesicular Stomatitis Virus–Based Vaccine by Use of the Mouse Model of Ebola Virus Hemorrhagic Fever [DOI]
132. 132 VP40 Octamers Are Essential for Ebola Virus Replication [DOI]
133. 133 Ebola Virus (EBOV) VP24 Inhibits Transcription and Replication of the EBOV Genome [DOI]
134. 134 FolateReceptor Alpha and Caveolae Are Not Required for Ebola VirusGlycoprotein-Mediated ViralInfection [DOI]
135. 135 Whole-Genome Expression Profiling Reveals That Inhibition of Host Innate Immune Response Pathways by Ebola Virus Can Be Reversed by a Single Amino Acid Change in the VP35 Protein [DOI]
136. 136 Recombinant Human Monoclonal Antibodies to Ebola Virus [DOI]
137. 137 Analysis of Filovirus Entry into Vero E6 Cells, Using Inhibitors of Endocytosis, Endosomal Acidification, Structural Integrity, and Cathepsin (B and L) Activity [DOI]
138. 138 Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology [DOI]
139. 139 Host IQGAP1 and Ebola Virus VP40 Interactions Facilitate Virus-Like Particle Egress [DOI]
140. 140 Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level [DOI]
141. 141 Ebola Virus VP30 Is an RNA Binding Protein [DOI]
142. 142 The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide [DOI]
143. 143 Comparative Analysis of Ebola Virus Glycoprotein Interactions With Human and Bat Cells [DOI]
144. 144 Structure‐Function Analysis of the Soluble Glycoprotein, sGP, of Ebola Virus [DOI]
145. 145 Role of VP30 Phosphorylation in the Ebola Virus Replication Cycle [DOI]
146. 146 Protective Efficacy of a Bivalent Recombinant Vesicular Stomatitis Virus Vaccine in the Syrian Hamster Model of Lethal Ebola Virus Infection [DOI]
147. 147 The Cys 3 -His 1 Motif of the Respiratory Syncytial Virus M2-1 Protein Is Essential for Protein Function [DOI]
148. 148 Structural Phosphoprotein M2-1 of the Human Respiratory Syncytial Virus Is an RNA Binding Protein [DOI]
149. 149 TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+T cells across the virological synapse [DOI]
150. 150 Ebola Virus, Neutrophils, and Antibody Specificity [DOI]
151. 151 Development of a preventive vaccine for Ebola virus infection in primates [DOI]
152. 152 Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice [DOI]
153. 153 Contribution of Ebola Virus Glycoprotein, Nucleoprotein, and VP24 to Budding of VP40 Virus-Like Particles [DOI]
154. 154 Ebola Virus VP30-Mediated Transcription Is Regulated by RNA Secondary Structure Formation [DOI]
155. 155 Productive Replication of Ebola Virus Is Regulated by the c-Abl1 Tyrosine Kinase [DOI]
156. 156 Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic [DOI]
157. 157 Characterization of the L gene and 5' trailer region of Ebola virus. [DOI]
158. 158 Identification of a Small-Molecule Entry Inhibitor for Filoviruses [DOI]
159. 159 Nedd4 Regulates Egress of Ebola Virus-Like Particles from Host Cells [DOI]
160. 160 Characterization of the Ebola virus nucleoprotein-RNA complex [DOI]
161. 161 Filovirus‐Like Particles Produced in Insect Cells: Immunogenicity and Protection in Rodents [DOI]
162. 162 Transcriptome Sequencing and Annotation for the Jamaican Fruit Bat (Artibeus jamaicensis) [DOI]
163. 163 Ebola virus disease - pathogenesis, clinical presentation and management.

Cited by 4

Showing 1 of 4 known citations — external sources report more than can currently be individually listed.

Related research

• Knowledge, Acceptance and Perception on COVID-19 Vaccine among Sudanese People in Khartoum State, 2020-2021 — shares topic coverage
• Aerosols in Dental Practice- A Neglected Infectious Vector — shares topic coverage
• Reports on COVID-19 Vaccines and Vaccination in Nigeria — shares topic coverage
• The New Pandemic Covid-19: Treatment Options and Developments — shares topic coverage
• Recent Advancements in Developing Animal Models for COVID-19 — shares topic coverage